Home › Funds › Burkehill Global Management, LP › BBIO
Burkehill Global Management, LP position in BBIO
BRIDGEBIO PHARMA INC · Health Care
Burkehill Global Management, LP reported holding 100,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$6.6M, representing 0.29% of its reported portfolio and ranking #44 among its reported holdings. Burkehill Global Management, LP has disclosed BBIO holdings in 3 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Burkehill Global Management, LP's BBIO position evolved
Burkehill Global Management, LP first disclosed a stake in BBIO in Q2 2025 at 275,000 shares (US$11.9M). The position peaked in Q3 2025 at 275,000 shares, worth US$14.3M. Across 3 filings, Burkehill Global Management, LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 100,000 shares valued at US$6.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 275.00K | $11.87M | New |
| Q3 2025 | 275.00K | $14.28M | Hold |
| Q3 2026 | 100.00K | $6.58M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 40 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$957.7M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 14.56M sh · $957.70M · Q3 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.25M sh · $937.45M · Q3 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.79M sh · $644.33M · Q3 2026
- Two Sigma Investments 3.66M sh · $240.83M · Q3 2026
- Aisling Capital Management LP 3.09M sh · $203.30M · Q3 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 104.89M sh · $162.63M · Q3 2026
- Paradigm Biocapital Advisors LP 2.35M sh · $154.49M · Q3 2026
- SC US (TTGP), LTD. 1.86M sh · $122.41M · Q3 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.39M sh · $91.65M · Q3 2026
More on Burkehill Global Management, LP
FAQ
How long has Burkehill Global Management, LP held BBIO?
Burkehill Global Management, LP has disclosed BBIO holdings in 3 of the last 6 reported quarters, going back to Q2 2025.
What is Burkehill Global Management, LP's current position in BBIO?
As of Q3 2026, Burkehill Global Management, LP holds 100.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $6.58M, representing 0.29% of its reported portfolio and ranking #44.
Has Burkehill Global Management, LP been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Burkehill Global Management, LP newly opened its position in BBIO. The position peaked in Q3 2025 at 275.00K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.